DNMT3A and acute myeloid leukemia: Similar to the results of patients with intermediate and adverse-cytogenetic risk, IPM-HR, older age, TP53 mutation, FLT3-ITD, and DNMT3A mutation were all independent adverse prognostic factors for OS in non-M3 AML patients (Table 1).